- Home
- STAA vs BEAM Comparison
STAA vs BEAM Comparison
Compare STAA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- BEAM
- Stock Information
- Founded
- STAA 1982
- BEAM 2017
- Country
- STAA United States
- BEAM United States
- Employees
- STAA N/A
- BEAM N/A
- Industry
- STAA Ophthalmic Goods
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STAA Health Care
- BEAM Health Care
- Exchange
- STAA Nasdaq
- BEAM Nasdaq
- Market Cap
- STAA 850.9M
- BEAM 1.6B
- IPO Year
- STAA N/A
- BEAM 2020
- Fundamental
- Price
- STAA $17.17
- BEAM $21.16
- Analyst Decision
- STAA Hold
- BEAM Strong Buy
- Analyst Count
- STAA 8
- BEAM 11
- Target Price
- STAA $27.17
- BEAM $48.90
- AVG Volume (30 Days)
- STAA 758.1K
- BEAM 2.3M
- Earning Date
- STAA 08-06-2025
- BEAM 08-05-2025
- Dividend Yield
- STAA N/A
- BEAM N/A
- EPS Growth
- STAA N/A
- BEAM N/A
- EPS
- STAA N/A
- BEAM N/A
- Revenue
- STAA $279,134,000.00
- BEAM $63,578,000.00
- Revenue This Year
- STAA N/A
- BEAM N/A
- Revenue Next Year
- STAA $27.83
- BEAM $17.18
- P/E Ratio
- STAA N/A
- BEAM N/A
- Revenue Growth
- STAA N/A
- BEAM N/A
- 52 Week Low
- STAA $13.50
- BEAM $13.53
- 52 Week High
- STAA $49.86
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- STAA 49.02
- BEAM 65.49
- Support Level
- STAA $16.52
- BEAM $19.02
- Resistance Level
- STAA $18.00
- BEAM $22.51
- Average True Range (ATR)
- STAA 0.69
- BEAM 1.15
- MACD
- STAA 0.09
- BEAM 0.49
- Stochastic Oscillator
- STAA 53.85
- BEAM 78.91
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.